Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Pretty simple observation, but if you can give double the standard dose to patients, it effectively doubles the size of the market. Let alone other people who could be eligible because of the better tolerance.
Market size for dox could easily triple to 4billion dollar market
Does any one know if there is a precedent for a drug being allowed in general use before finishing it's full trials ie the results are so good ( COVID related apart)
I was thinking of the Beatson hospital starting with head and neck, then a couple of weeks later recruiting for breast cancer.
Almost like they are saying what else is this going to work on and let's get more people on it
My takeaway from being at the meeting.
Al started presentation with saying he really wanted to fully concentrate on AV6000. Even though affimers had lots going on. Why do that if it was failing. Most CEOs just move onto the next big thing with barely a mention of the last oneo
The decision to go to cohort 3 and or 4 dose escalation was completely in the hands of the clinicians. The decision on when to go to 1 b and what dosage even if the mtd wasn't reached is with the clinicians, not Avacta
Did sound as tho Al thought we might not reach mtd. But with the caveat that it had to be shown to be in the tumour otherwise it might not have been cleaved at all.
Interesting comment re the dead duck lft. He said our test was very sensitive into the low 30s but with Omicron it dropped to the mid 20s. ( I reckon that was probably on a par with everyone else yet they pulled it. High Standards)
Final point. He is adamant about keeping AV6000 But the the opportunity for licensing a product or the platform( I think more likely) will come as SOON as they have the complete phase 1a data !!
So not that long.
Dr Brian Min, Chief Executive Officer of GenScript ProBio commented:
"We are pleased to partner with AffyXell and are honored to support this next-generation cell therapy project with GenScript ProBio's stable and high-yield viral vector platform. We expect many patients to benefit from this innovative genetically modified mesenchymal stem cells therapy soon."
I wonder if his idea of soon is anywhere near mine?
As Fiona said about consistent data across different tumour types. That is very good news as it seems to be working in different types of tumour at different stages of their progression.
Both them happy with the data.Probably as much as they could say
Beinthelead. Rns's speak to a tiny audience. Now they have the ears of the press.
You obviously never worked in sales where you pursue every opportunity to get your name out there. Do youthink Al contacted his local MP?
If you sit there waiting for it to come to you, it doesnt.
Lateral flow test shortages are all the rage in the papers and news. The BBC, Guardian and Sky news would be all over the opportunity to castigate the Government. Can you imagine if Michael O Leary(Ryanair) had this opportunity, he would be all over the airways.
Where is AS asleep in his bed? Our PR company?
Both useless at marketing and publicity.
Good job the science is good
Unfortunately, there's another small BRITISH diagnostic company Abingdon Health, again having to take the government to court for payment of an invoice for £0.5 million. It has had to lay workers off , and raise money to keep going, and is going to be a manufacturer of the Avacta test
We are talking small amounts for British cos whilst giving BILLIONS to Chinese rebadged rubbish tests
All this is verifiable in the news outputs of the various companies.
So instead of helping, you lot are doing a very good job of hampering, if not in fact destroying our diagnostics industry, whilst helping Chinese manufacturing. You couldn't make it up.
Incompetence or Corruption. Neither are very appealing. But this is what your party is now associated with
Hope the email wasn't too long, Don't want to keep you out of the Westminster bubble for too long
Kind regards
to Matthew.offord.mp
Hi Matthew
I normally can't be bothered to write to my MP. I think once before, many years ago.
Firstly I have voted conservative since about 1979 and voted for Brexit. Unfortunately the debacles recently, don't shine a great light on the party. When a government begins to believe it's above the people and the law, it is the beginning of the end. Trying to defend Owen Patterson, spoke of the old boys club and the Xmas parties just about finished it. (Incompetence)
What I really wanted to bring to your attention, as it has come to mine (and again this stinks of behind closed doors old boys deals ) is the money spent on Chinese flow tests.
I seem to remember Boris talking about making the BRITISH diagnostic market a powerhouse.
I don't suppose you even know, that probably the best lateral flow test in the world is British? Using BRITISH technology and BRITISH patents. No it doesnt cost £50 or something ridiculous it is about the same as the others.
It is made by Avacta life Science (based in yorkshire) What The government has actually done to the BRITISH diagnostics industry is F**ked most of it over (sorry for the language i am seething about this, more than 1.4 billion pounds and counting to probably our mortal enemy)
The Avacta lateral flow test identifies 100% cases up to 27 PCRct viral load ( it appears that the best Chinese one maybe 80%) and 98% thereafter INTO pcr territory. With 99% specificity (ie false positives) Absolutely brilliant results
The avacta test uses the spike in the virus to identify it, and this is where the problem seems to come at Porton Down. They use Frozen samples which may alter the spike but not the nucleus that others use,and so it is not passing. But in real life with live virus, used by normal people as it would be, tested independently by a renowned clinic in the Spain Carlos III Hospital in Madrid it gives the above figures And they have just announced it identifies Omicron as well.
I cannot believe any other country, USA, France, China, Japan would not prioritise their own country's industry, and do everything they could to promote it. This was the idea of BREXIT. How difficult does it make it for Avacta to sell abroad, which they are attempting to do, when others turn round to them and say, but your own government isn't buying it.
But this is not the end. Lets move onto another small BRITISH diagnostic company Omega diagnostics. You remember the flagship lateral flow test (it should be Avactas but somebody has taken a backhander to have a Chinese one rebadged it appears) Omega were lent equipment and money £2.5m to produce it by the DHSC. but they never decided on a test to manufacture. So now they want the money back. Omega acted in good faith using some of their own funds as well to set up the pre production facilities They are confident having taken legal advise, they will not be required to repay this. It is having a terrible effect on the compa
After reading page 5/6, I know it's been said before but our test looks to have passed every aspect of those criteria with flying colours. I can't imagine many will when you take into account the >25ct results up to 36
hTTps://www.lse.co.uk/rns/EVG/early-data-for-sfx-01-in-leukaemia-cell-lines-eji7wn28i192dug.html
1 day late what's the matter with you. A week woudn't be that far out. It's a 3rd party show. Grow up
If the prof found anything he is going to want it statistically correct. Not pulled to pieces in a peer review. Anyway the delay is not going to change the result, just gives you more time to get out if you fear the worst as the drop on bad news will be the same any day of the week.
My hope here is if it was bad news with no effect it would be released a lot quicker than if you are evaluating the perceived beneficial effects as a percentage in any given scenario.
Let's hope so anyway